Our free daily oncology focused e-news service.

Featured Oncology News

Bayer's Stivarga Shows Slim Progress Against Liver Cancer

(Forbes) Apr 27, 2017 - Today the FDA approved a new drug—one of few available—for treating liver cancer. Regorafenib is a pill manufactured by Bayer and sold as Stivarga. Already it’s been approved for use in some patients with refractory colon, rectal, and GI stromal tumors.

read article

Congressman, Pharmacist, and Lawyer Debate PBMs, Drug Prices at Annual COA Meeting

(AJMC.com) Apr 27, 2017 - At the 2017 Community Oncology Conference, participants discussed the impact of pharmacy benefit managers (PBMs) on oncology drug prices and patient access to much needed treatments.

read article

Novartis Receives FDA Approval for Rydapt® in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)

(Novartis) Apr 28, 2017 - Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than 25 years; Rydapt treatment regimen in FLT3-mutated AML demonstrated a significant improvement in overall survival with a 23% reduction in the risk of death; Rydapt is the first and only approved therapy for three types of SM collectively known as advanced SM, a group of ultra-rare, life-threatening conditions.

read corporate press release

Oncology Clinical News

Some Women Choosing Unnecessarily Radical Surgeries for Early-Stage Cancer

(Yahoo! Finance) Apr 27, 2017 - New study finds low risk of contralateral breast cancer does not justify bilateral mastectomy for DCIS patients.

read article

Lymphedema Is 'Multimodal Insult,' Say Breast Surgeons

(Medscape Medical News) Apr 28, 2017 - The risk for lymphedema in patients with breast cancer is not solely tied to surgery but is also associated with multiple other factors, including radiation therapy and chemotherapy, new research confirms.

read article (free registration required)

Guide to Preventing Fractures in Patients With Breast Cancer on AIs

(Medscape Medical News) Apr 27, 2017 - New position statement provides a template for physicians to prevent fractures in postmenopausal women receiving aromatase inhibitor (AI) therapy for breast cancer.

read article (free registration required)

Study Examines New Breast Cancer Drug Combination

(VICC) Apr 27, 2017 - A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy.

read article

Treatment Improved 5-year Overall Survival in Elderly Patients with Early-Stage Esophageal Cancer

(IASLC) Apr 27, 2017 - Elderly patients with early-stage esophageal cancer that received treatment had an increased 5-year overall survival when compared to patients who received observation with no treatment.

read press release

Dramatic Jump in Incidence of NETs Over Past 4 Decades

(Medscape Medical News) Apr 27, 2017 - The incidence of neuroendocrine tumors (NETs) has increased dramatically over the past 4 decades, but the rise may be due to improved diagnosis.

read article (free registration required)

Genmab Announces New Phase III Combination Study of Daratumumab in Multiple Myeloma

(finanznachrichten.de) Apr 28, 2017 - Genmab A/S announced today that Janssen Research & Development, LLC, in collaboration with the European Myeloma Network (EMN) and Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), plans to start a Phase III study of daratumumab in relapsed and refractory multiple myeloma.

read article

Oncology Business and Policy News

April 28: COA Compendium Paper Collects Findings from 25 Years of 340B Drug Discount Program Research

(COA) Apr 28, 2017 - A compendium released today by the Community Oncology Alliance (COA) compiles the findings of research studies, white papers, and analyses looking at the growth and impact of the 340B Drug Discount Program on the United States healthcare system over the last 25 years.

read press release

Oncology Practice Administrators Discuss Early Findings From the OCM

(AJMC.com) Apr 27, 2017 - At the 2017 Community Oncology Conference, practice administrators from 2 community clinics discussed the changes they made to their practice to accommodate the reporting requirements of the Oncology Care Model (OCM), and the follow-up planned as they work to implement changes.

read article

Shared Decisions in Cancer Care: Is Medicare Providing a Model?

(Urban Institute) Apr 23, 2017 - Medicare’s Oncology Care Model (OCM) is designed to incentivize providers to reduce unnecessary spending, improve care, and involve patients more closely in decisions about the use of chemotherapy.

read article

Linking Claims, Clinical Data Is Essential for a Learning Health System

(AJMC.com) Apr 28, 2017 - Is rubber meeting the road with big data in cancer care? “No…rather, not yet,” Green said at the 2017 Community Oncology Conference, April 26-27, held at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

read article

Annals of Oncology Press Release: England’s Cancer Drugs Fund ‘Failed to Deliver Meaningful Value to Patients and Society’

(ESMO) Apr 28, 2017 - Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may have resulted in patients suffering unnecessarily from toxic side effects of the drugs.

read press release

NICE U-Turn Recommends Some Access to Takeda's Adcetris

(PharmaTimes [UK]) Apr 28, 2017 - It is now looking likely that some patients with relapsed/refractory (R/R) Hodgkin lymphoma will be able to get routine access to Takeda’s Adcetris on the NHS after a major u-turn by cost regulators.

read article

Takeda's Ninlaro Rejected by NICE for Multiple Myeloma

(PharmaTimes [UK]) Apr 27, 2017 - Takeda has vowed to work with the National Institute for Health and Care Excellence to get NHS funding approved for its mutilple myeloma drug Ninlaro following an initial rejection by the cost watchdog.

read article

Broader Healthcare and Pharma News

BioMarin Wins FDA Approval for Life-Changing Drug for Kids — with a $700,000-per-year Cost

(San Francisco Business Times) Apr 27, 2017 - Rare disease drug developer BioMarin Pharamceutical Inc. won regulatory approval Thursday of a drug that promises to change the course of a fatal childhood neurodegenerative disease.

read article

Mark Zuckerberg and Priscilla Chan's Philanthropy Backs Effort To Change Scientific Publishing

(Forbes) Apr 26, 2017 - The Chan Zuckerberg Initiative, the philanthropic investment vehicle created by Facebook founder Mark Zuckerberg and his wife, Priscilla Chan, M.D., will fund an effort to allows biologists to share drafts of papers before they are published in peer-reviewed scientific journals like Nature or Science.

read article